KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Capital Leases (2016 - 2017)

Nektar Therapeutics (NKTR) has 8 years of Capital Leases data on record, last reported at $3.0 million in Q3 2017.

  • For Q3 2017, Capital Leases rose 39.99% year-over-year to $3.0 million; the TTM value through Sep 2017 reached $3.0 million, up 39.99%, while the annual FY2016 figure was $2.2 million, 107.18% up from the prior year.
  • Capital Leases reached $3.0 million in Q3 2017 per NKTR's latest filing, down from $3.8 million in the prior quarter.
  • Across five years, Capital Leases topped out at $10.8 million in Q1 2013 and bottomed at $1.1 million in Q4 2015.
  • Average Capital Leases over 5 years is $5.4 million, with a median of $5.3 million recorded in 2014.
  • Peak YoY movement for Capital Leases: skyrocketed 121.53% in 2016, then crashed 80.14% in 2017.
  • A 5-year view of Capital Leases shows it stood at $8.0 million in 2013, then tumbled by 48.58% to $4.1 million in 2014, then crashed by 74.08% to $1.1 million in 2015, then skyrocketed by 107.18% to $2.2 million in 2016, then skyrocketed by 34.95% to $3.0 million in 2017.
  • Per Business Quant database, its latest 3 readings for Capital Leases were $3.0 million in Q3 2017, $3.8 million in Q2 2017, and $1.6 million in Q1 2017.